Final published version
Licence: CC BY-NC-ND: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Research output: Contribution to Journal/Magazine › Journal article › peer-review
}
TY - JOUR
T1 - Beta-Secretase-1 Antisense RNA Is Associated with Vascular Ageing and Atherosclerotic Cardiovascular Disease
AU - Bampatsias, Dimitrios
AU - Mavroeidis, Ioannis
AU - Tual-Chalot, Simon
AU - Vlachogiannis, Nikolaos I
AU - Bonini, Francesca
AU - Sachse, Marco
AU - Mavraganis, Georgios
AU - Mareti, Alexia
AU - Kritsioti, Chrysoula
AU - Laina, Ageliki
AU - Delialis, Dimitrios
AU - Ciliberti, Giorgia
AU - Sopova, Kateryna
AU - Gatsiou, Aikaterini
AU - Martelli, Fabio
AU - Georgiopoulos, Georgios
AU - Stellos, Konstantinos
AU - Stamatelopoulos, Kimon
N1 - The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).
PY - 2022/11/30
Y1 - 2022/11/30
N2 - Background The noncoding antisense transcript for β-secretase-1 (BACE1-AS) is a long noncoding RNA with a pivotal role in the regulation of amyloid-beta; (Abeta;). We aimed to explore the clinical value of BACE1-AS expression in atherosclerotic cardiovascular disease (ASCVD). Methods Expression of BACE1-AS and its target, beta;-secretase 1 (BACE1) mRNA, was measured in peripheral blood mononuclear cells derived from 434 individuals (259 without established ASCVD [non-CVD], 90 with stable coronary artery disease [CAD], and 85 with acute coronary syndrome). Intima-media thickness and atheromatous plaques evaluated by ultrasonography, as well as arterial wave reflections and pulse wave velocity, were measured as markers of subclinical ASCVD. Patients were followed for a median of 52 months for major adverse cardiovascular events (MACE). Results In the cross-sectional arm, BACE1-AS expression correlated with BACE1 expression (r.0.396, p<0.001) and marginally with Abeta;1.40 levels in plasma (r.0.141, p.0.008). Higher BACE1-AS was associated with higher estimated CVD risk assessed by HeartScore for non-CVD subjects and by European Society of Cardiology clinical criteria for the total population (p<0.05 for both). BACE1-AS was associated with higher prevalence of CAD (odds ratio [OR]=1.85, 95% confidence interval [CI]: 1.37-2.5), multivessel CAD (OR=1.36, 95% CI: 1.06-1.75), and with higher number of diseased vascular beds (OR=1.31, 95% CI: 1.07-1.61, for multiple diseased vascular beds) after multivariable adjustment for traditional cardiovascular risk factors. In the prospective arm, BACE1-AS was an independent predictor of MACE in high cardiovascular risk patients (adjusted hazard ratio=1.86 per ascending tertile, 95% CI: 1.011-3.43, p=0.046). Conclusion BACE1-AS is associated with the incidence and severity of ASCVD.
AB - Background The noncoding antisense transcript for β-secretase-1 (BACE1-AS) is a long noncoding RNA with a pivotal role in the regulation of amyloid-beta; (Abeta;). We aimed to explore the clinical value of BACE1-AS expression in atherosclerotic cardiovascular disease (ASCVD). Methods Expression of BACE1-AS and its target, beta;-secretase 1 (BACE1) mRNA, was measured in peripheral blood mononuclear cells derived from 434 individuals (259 without established ASCVD [non-CVD], 90 with stable coronary artery disease [CAD], and 85 with acute coronary syndrome). Intima-media thickness and atheromatous plaques evaluated by ultrasonography, as well as arterial wave reflections and pulse wave velocity, were measured as markers of subclinical ASCVD. Patients were followed for a median of 52 months for major adverse cardiovascular events (MACE). Results In the cross-sectional arm, BACE1-AS expression correlated with BACE1 expression (r.0.396, p<0.001) and marginally with Abeta;1.40 levels in plasma (r.0.141, p.0.008). Higher BACE1-AS was associated with higher estimated CVD risk assessed by HeartScore for non-CVD subjects and by European Society of Cardiology clinical criteria for the total population (p<0.05 for both). BACE1-AS was associated with higher prevalence of CAD (odds ratio [OR]=1.85, 95% confidence interval [CI]: 1.37-2.5), multivessel CAD (OR=1.36, 95% CI: 1.06-1.75), and with higher number of diseased vascular beds (OR=1.31, 95% CI: 1.07-1.61, for multiple diseased vascular beds) after multivariable adjustment for traditional cardiovascular risk factors. In the prospective arm, BACE1-AS was an independent predictor of MACE in high cardiovascular risk patients (adjusted hazard ratio=1.86 per ascending tertile, 95% CI: 1.011-3.43, p=0.046). Conclusion BACE1-AS is associated with the incidence and severity of ASCVD.
KW - Humans
KW - Aging
KW - Amyloid Precursor Protein Secretases/genetics
KW - Aspartic Acid Endopeptidases/genetics
KW - Atherosclerosis/genetics
KW - Cardiovascular Diseases/genetics
KW - Carotid Intima-Media Thickness
KW - Cross-Sectional Studies
KW - Leukocytes, Mononuclear/metabolism
KW - Prospective Studies
KW - Pulse Wave Analysis
KW - RNA, Antisense
KW - RNA, Long Noncoding/genetics
U2 - 10.1055/a-1914-2094
DO - 10.1055/a-1914-2094
M3 - Journal article
C2 - 35915966
VL - 122
SP - 1932
EP - 1942
JO - Thrombosis and Haemostasis
JF - Thrombosis and Haemostasis
SN - 0340-6245
IS - 11
ER -